Pliant Therapeutics Inc (NASDAQ:PLRX) — Market Cap & Net Worth
Market Cap & Net Worth: Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics Inc (NASDAQ:PLRX) has a market capitalization of $69.97 Million ($69.97 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20694 globally and #4683 in its home market, demonstrating a -1.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pliant Therapeutics Inc's stock price $1.13 by its total outstanding shares 61921897 (61.92 Million). Also see PLRX total assets for a full breakdown of the balance sheet.
Pliant Therapeutics Inc Market Cap History: 2020 to 2026
Pliant Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $1.41 Billion to $69.97 Million (-37.29% CAGR). Also see Pliant Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Pliant Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #593 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1987 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.00% | #246 of 263 |
Weight: Pliant Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pliant Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pliant Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PLRX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
709.75x
Pliant Therapeutics Inc's market cap is 709.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.41 Billion | $41.82 Million | -$39.74 Million | 33.64x | N/A |
| 2021 | $835.95 Million | $7.57 Million | -$17.91 Million | 110.40x | N/A |
| 2022 | $1.20 Billion | $9.69 Million | -$123.32 Million | 123.59x | N/A |
| 2023 | $1.12 Billion | $1.58 Million | -$161.34 Million | 709.75x | N/A |
Competitor Companies of PLRX by Market Capitalization
Companies near Pliant Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Pliant Therapeutics Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pliant Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Pliant Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Pliant Therapeutics Inc's market cap moved from $1.41 Billion to $ 69.97 Million, with a yearly change of -37.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $69.97 Million | -7.38% |
| 2025 | $75.54 Million | -90.74% |
| 2024 | $815.51 Million | -27.28% |
| 2023 | $1.12 Billion | -6.31% |
| 2022 | $1.20 Billion | +43.19% |
| 2021 | $835.95 Million | -40.58% |
| 2020 | $1.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Pliant Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.97 Million USD |
| MoneyControl | $69.97 Million USD |
| MarketWatch | $69.97 Million USD |
| marketcap.company | $69.97 Million USD |
| Reuters | $69.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more